Meta-Analysis
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. May 26, 2023; 15(5): 273-283
Published online May 26, 2023. doi: 10.4330/wjc.v15.i5.273
Impact of erythropoietin therapy on cardiorenal syndrome: A systematic review with meta-analysis
Rubal Bhangal, Ivan Cancarevic, Mahmoud Nassar, Zaryab Umar
Rubal Bhangal, Ivan Cancarevic, Zaryab Umar, Department of Internal Medicine, Icahn School of Medicine at Mount Sinai/NYC Health+Hospitals Queens, New York, NY 11432, United States
Mahmoud Nassar, Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States
Mahmoud Nassar, Department of Internal Medicine, NYC Health+Hospital Queens, New York, NY 11432, United States
Author contributions: All author contributed equally; All authors have read and approved the final version.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mahmoud Nassar, MD, MSc, PhD, Doctor, Department of Internal Medicine, NYC Health+Hospital Queens, New York, NY 11432, United States. dr.nassar@aucegypt.edu
Received: December 19, 2022
Peer-review started: December 19, 2022
First decision: February 8, 2023
Revised: March 24, 2023
Accepted: April 4, 2023
Article in press: April 4, 2023
Published online: May 26, 2023
Core Tip

Core Tip: Erythropoietin improves baseline hemoglobin levels and decreases the risk of major cardiovascular.